Infliximab: An alternative treatment for refractory immune thrombocytopenic purpura related to Crohnʼs disease?

Lazaraki, Georgia; Metallidis, Simeon; Giannoulis, Kleanthis; Tarpagos, Anestis

doi:10.1002/ibd.20209

Cited by 7 publications

(9 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mucosal production of type 1 helper T cells (T h 1) proinflammatory cytokines, such as TNF-alpha, is known to be increased in CD [2,21]. Moreover, T h 1 responses may mediate both acute ITP and CD [21].…”

Section: Anti-tnf-alpha Antibodies For the Treatment Of Concomitant Imentioning

confidence: 99%

“…Potential mechanisms of action of anti-TNF-alpha therapies include apoptotic and cytotoxic effects on monocytes and macrophages (the major producers of soluble TNF-alpha) and subsequent decreases in antiplatelet antibody production by B lymphocytes [2,21]. De Rossi et al [34] proposed the use of anti-TNF-alpha antibodies as an efficient and relatively costefficient treatment in cases of ITP, particularly when concomitant with CD.…”

Section: Anti-tnf-alpha Antibodies For the Treatment Of Concomitant Imentioning

confidence: 99%

“…De Rossi et al [34] proposed the use of anti-TNF-alpha antibodies as an efficient and relatively costefficient treatment in cases of ITP, particularly when concomitant with CD. Infliximab may be considered in patients refractory to standard therapies for concomitant CD and ITP [2,34,35].…”

Section: Anti-tnf-alpha Antibodies For the Treatment Of Concomitant Imentioning

confidence: 99%

“…CD is a chronic recurrent disease characterized by intestinal inflammation due to genetic, immunological, and environmental factors [1]. Aberrant T lymphocyte autoreactivity (innate and adaptive immune responses to a subset of commensal enteric bacteria) is a major component of the immunological dysfunction observed in CD patients [2]. CD involves the entire bowel wall and may affect any part of the gastrointestinal tract.…”

Section: Introductionmentioning

confidence: 99%

“…CD involves the entire bowel wall and may affect any part of the gastrointestinal tract. Furthermore, the development of extraintestinal manifestations, including a range of autoimmune diseases, is observed in 20-40% of patients with CD [2,3].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Concomitant Immune Thrombocytopenic Purpura and CrohnÃ¢ÂÂs Disease

Shizuma¹

2015

J Blood Disord Transfus

View full text Add to dashboard Cite

The coexistence of immune (idiopathic) thrombocytopenic purpura (ITP) and Crohn's disease (CD) is rare. We performed a review of cases of concomitant ITP and CD in the English and Japanese literature. Among 17 identified cases of concomitant ITP and CD, ITP was initially diagnosed in four cases and CD was initially diagnosed first in six cases. Simultaneous diagnoses were reported in the remaining seven cases. No fatalities were reported in any of the 17 cases. However, resistance or transient responses to standard therapies, such as glucocorticoids or intravenous immunoglobulin (IVIG), and splenectomy for the treatment of ITP were reported in a number of concomitant cases. Moreover, the administration of anti-tumor necrosis factor (TNF)-alpha antibodies was a commonly considered pharmacological therapy in cases of concomitant ITP and CD.

show abstract

Section: Anti-tnf-alpha Antibodies For the Treatment Of Concomitant Imentioning

confidence: 99%

Section: Anti-tnf-alpha Antibodies For the Treatment Of Concomitant Imentioning

confidence: 99%

Section: Anti-tnf-alpha Antibodies For the Treatment Of Concomitant Imentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Concomitant Immune Thrombocytopenic Purpura and CrohnÃ¢ÂÂs Disease

Shizuma¹

2015

J Blood Disord Transfus

View full text Add to dashboard Cite

show abstract

Severe adalimumab-induced thrombocytopenia in a patient with Crohn's disease

Casanova

Chaparro

et al. 2012

Journal of Crohn's and Colitis

View full text Add to dashboard Cite

Crohn's disease is a chronic transmural inflammatory disorder characterized by inflammation of the intestine. Anti-TNF-α drugs are used for induction and maintenance of remission in patients with this condition. Thrombocytopenia is an uncommon side effect of treatment with anti-TNF-α drugs. We report the case of a 71-year-old woman diagnosed with Crohn's disease who developed severe adalimumab-induced thrombocytopenia and who did not respond to standard therapy for thrombocytopenia.

show abstract